What is NeuroPace's gross profit margin?

What were the key takeaways from NeuroPace’s earnings call?

What is the revenue and EPS growth rate for NeuroPace year over year?

Did NeuroPace beat or miss consensus estimates last quarter?

What is the market's earnings forecast for NeuroPace next quarter?

What guidance did NeuroPace's management provide for the next earnings period?

What does NeuroPace do and what are its main business segments?

What is NeuroPace's latest dividend and current dividend yield?

- **25% RNS System growth**: 2026 epilepsy AI adoption (75%+ Seizure ID penetration).

**【CEO Summary Section】**
- NeuroPace reported 25% year-over-year revenue growth in Q4 2025, driven by expanded RNS System adoption in Level 4 epilepsy centers.
- The company emphasized 2026 guidance for $98-100 million in RNS revenue, supported by 20%+ procedural volume increases in adult focal epilepsy.
- Seizure ID AI platform achieved 80%+ physician workflow efficiency in Q4, reducing review times by 30% in 2025.

**【CFO Financial Commentary】**
- Adjusted EBITDA margin improved to 77.4% (up 200bps YoY) amid disciplined cost management.
- RNS System ASPs increased 18% with higher-margin IGE procedures.
- 2026 capital allocation prioritizes pediatric epilepsy, generalized seizure, and cloud-based analytics.

**【Q&A Highlights】**
- Q4 Seizure ID adoption exceeded 75% in Level 4 centers.
- 2026 IGE pipeline projects $12 million in 2026, with 75%+ AI utilization.
- Pediatric epilepsy trials expand to 15 countries in Q1 2026.
- 2026 R&D focuses on 12-lead ECoG arrays and 3D seizure mapping.
- 2026 gross margin targets 82% with 15%+ cost reductions.
- 2026 epilepsy market projects $1.2 billion in neurodiagnostics, 2026 AI penetration rates 2026-2030.

NeuroPace, Inc.(NPCE)-20260304-2025 Q4 Earnings call transcript

- **Revenue Beat**: Q3 $27.4M (+30% YoY), RNS up 31% to $22.6M, DIX Milestone**: First positive EBITDA, grossI winding down.
- **Margin margin 77.4% (vs 73.2% YoY), 2025 guide 76-77%.
- **Pipeline Catalysts**: NAUTILUS PMA Q4, pediatric PMA via real-world evidence, Seizure ID FDA submission.
- **Growth Drivers**: 20%+ RNS core, growth AI tools, and expanding into Level 3/Community centers.
- **Operational Strength**: $60M cash, 21% opex vs 30% rev, disciplined expense mgmt.

**【CEO Summary Section】**
- **Record Revenue Growth**: Q3 revenue of $27.4M, up 30% YoY, driven by RNS System sales of $2% YoY growth). 
- **R2.6M (31NS Expansion**: Broad-based utilization across geographies, with Level 4 centers leading procedural volumes. Direct-to-consumer efforts and Project CARE contributed to growth.
- **Gross Margin Milestone**: First quarter of positive adjusted EBITDA, reflecting operational efficiency.
- **Pipeline Progress**: NAUTILUS PMA supplement submission on track for Q4, pediatric indication collaboration with FDA ongoing.
- **AI Integration**: Seizure ID AI tool submitted to FDA, part of broader AI-enabled neuromodulation suite.

**【CFO Financial Commentary】**
- **Revenue Guidance Update**: Full year 2025 revenue raised to $97-98M (21-23% YoY growth), driven by RNS System strength.
- **Gross Margin Expansion**: Q3 gross margin 77.4%, up from 73.2% YoY, with RNS >80% margin. 2025 gross margin guidance raised to 76-77%.
- **Operating Leverage**: Operating expenses up 21% YoY but below revenue growth (30%), with focus on R&D and sales overperformance.
- **Cash Flow**: $60M cash balance, supporting DIXI wind-down (Q1 2026 completion).

**【Q&A Highlights】**
- **2026 Outlook**: RNS core growth 20%+; NAUTILUS PMA expected mid-2026; pediatric strategy using real-world evidence.
- **Gross Margin Stability**: 80%+ RNS margin sustainable post-DIXI; service revenue monetizes data partnerships.
- **Competitive Position**: Outpacing peers via market expansion (Level 4 centers) and tech differentiation (closed-loop AI).
- **Pipeline Momentum**: Seizure ID AI tool first of suite; IGE PMA submission Q4; pediatric PMA via real-world evidence collaboration.
- **Replacement Revenue**: <10% of total, but growing as initial implants mature; focus on RNS initial sales for now.

NeuroPace, Inc. (NPCE) Q3 2025 Earnings Call Transcript

- **Revenue Growth Accelerates**: Q2 2025 revenue up 22% YoY to $23.5M, driven by RNS System sales growth of 16%.
- **Gross Margin Expansion**: Total gross margin 77.1%, RNS System >80%, with target to reach 80%+ post-DIXI phase-out.
- **NAUTILUS Trial Success**: 80%+ GTC seizure reduction at 18-24 months, 45.2% seizure-free at 12 months, supporting FDA submission for IGE indication.
- **AI Innovation**: 22 million+ event database powers next-gen seizure classifier, with first AI tools launching in 2025.
- **Financial Strength**: Free cash flow improved to -$2.3M Q2, debt refinancing reduces annual interest expense by $2M.

**【CEO Summary Section】**
- Q2 2025 revenue reached $23.5 million, up 22% YoY, driven by RNS System sales growth of 16% and Project CARE contributions.
- Gross margin improved to 77.1%, with RNS System gross margin exceeding 80%.
- Raised full-year revenue guidance to $94-$98 million (18%-23% YoY growth) and gross margin to 75%-76%.
- Completed debt refinancing, reducing interest expense by $2 million annually.
- NAUTILUS trial data shows 80%+ GTC seizure reduction at 18-24 months, with 45.2% seizure-free patients at 12 months.
- AI-powered seizure classifier now analyzes over 22 million events, enhancing clinical insights.

**【CFO Financial Commentary】**
- Q2 GAAP net loss: $8.7 million (vs. $7.5 million YoY), with free cash flow improving to -$2.3 million (vs. -$4 million YoY).
- Operating expenses grew 13% YoY to $25 million, below revenue growth rate.
- R&D expenses: $6.8 million (12% YoY increase), supporting next-gen platform development.
- DIXI Medical sales to phase out by Q1 2026, enabling gross margin to trend toward 80%.

**【Q&A Key Highlights】**
- **FDA Submission Strategy**: Pursuing broad IGE indication based on NAUTILUS secondary endpoints (80%+ GTC reduction, 45.2% seizure-free at 12 months).
- **Gross Margin Outlook**: Targeting 80%+ RNS gross margin post-DIXI wind-down, with cash flow breakeven by 2027.
- **Project CARE**: Sequential implant volume growth, with community centers contributing 13% of total implants.
- **AI Development**: First AI tools expected to launch in 2025, enhancing seizure detection and therapy optimization.
- **Reimbursement**: CMS preserved RNS DRG structure for FY26, avoiding reimbursement uncertainty.
- **Partnerships**: Collaborating with UCB and Rapport to leverage 22M+ event database for therapeutic insights.

NeuroPace, Inc. (NPCE) Q2 2025 Earnings Call Transcript

- **Revenue Growth Accelerates**: Q1 2025 revenue up 24% YoY to $22.5M, driven by 29% RNS growth (ex NAUTILUS). 
- **Margin Expansion**: Gross margin jumps to 77% vs. 73.6% last year, targeting 73-75% for 2025. 
- **Strategic Shift**: SEEG exit frees resources for RNS (78%+ margin vs. 50% SEEG), with 20%+ CAGR through 2027. 
- **Clinical Momentum**: NAUTILUS IGE study on track for H2 2025 FDA submission; pediatric epilepsy data leverages 27-center real-world evidence. 
- **Cash Position**: $66.3M cash post-$75M equity raise, on track for 2027 breakeven.

**【CEO Summary Section】**
- Q1 2025 revenue reached $22.5 million, up 24% YoY, driven by 26% growth in RNS sales (29% excluding NAUTILUS implants). 
- Project CARE contributed to record prescriber numbers and Level 4 center adoption. 
- Termination of SEEG distribution to focus on high-margin RNS business (78%+ gross margin vs. 50% for SEEG). 
- 2025 revenue guidance raised to $93-97 million (16-21% YoY growth), with CAGR >20% through 2027. 
- NAUTILUS IGE study on track for H2 2025 FDA submission. 
- Pediatric epilepsy expansion using real-world data from 27 centers and 25+ peer-reviewed studies. 

**【CFO Financial Commentary】**
- Q1 2025 gross margin improved to 77% (vs. 73.6% Q1 2024) due to RNS manufacturing scale and price increases. 
- R&D expenses rose 27% to $7.4 million for AI software and next-gen device development. 
- Operating expenses grew 8% to $22.5 million, with strong operating leverage (24% revenue growth vs. 8% expense growth). 
- Net loss narrowed to $6.6 million (from $8.9 million), with cash balance of $66.3 million post-$75M equity raise. 

**【Q&A Highlights】**
- **Gross Margin Sustainability**: 77% Q1 margin driven by RNS volume and pricing; expect 73-75% for 2025 due to SEEG transition. 
- **Project CARE Impact**: CARE centers contributed 20%+ of new implants, with Level 4 centers seeing 30%+ adoption rate. 
- **SEEG Transition**: SEEG revenue to decline 50% YoY, but RNS growth offsets impact. 
- **Direct-to-Patient Strategy**: Digital campaigns and Nurse Navigator team increased patient engagement by 20% QoQ. 
- **NAUTILUS Data**: 82% seizure reduction at 3 years vs. 44% for VNS; on track for H2 2025 FDA filing.

NeuroPace, Inc. (NPCE) Q1 2025 Earnings Call Transcript

- **Revenue Momentum**: 22% YoY growth to $79.9M in 2024, with Q4 up 19% YoY. 2025 guidance of $92-96M reflects 15-20% growth.
- **Strategic Expansion**: Project CARE implants/referrals doubled in 2024, with 2025 target to more than double again. NAUTILUS study for idiopathic generalized epilepsy expected to read out in H2 2025.
- **Clinical Impact**: 42.5% of patients in post-approval study achieved 6+ months seizure freedom. Pediatric indication expansion in collaboration with FDA.
- **Financial Health**: 75.4% gross margin in Q4, with operating expenses up only 7% YoY. Pro forma cash of $68.6M post-public offering.
- **Capital Allocation**: $49.5M used to repurchase shares, ending ATM program and reducing overhang.

**【CEO Summary Section】**
- **Revenue Growth**: Total 2024 revenue reached $79.9 million, up 22% YoY, driven by RNS System and DIXI Medical sales. Q4 revenue was $21.5 million, a 19% YoY increase.
- **Three-Part Strategy**: 
  1. Expand adoption/utilization in Level 4 epilepsy centers (est. $2B annual market). 
  2. Launch Project CARE to deliver RNS therapy outside Level 4 centers. 
  3. Expand RNS System indications for idiopathic generalized epilepsy and pediatrics.
- **Clinical Progress**: 
  - 3-year safety/effectiveness data from post-approval study showed 42.5% of patients achieved 6+ months seizure freedom. 
  - NAUTILUS pivotal study for idiopathic generalized epilepsy expected to read out in H2 2025. 
  - Pediatric indication expansion in collaboration with FDA and NEST.
- **Financial Discipline**: Maintained 75.4% gross margin in Q4, with operating expenses up only 7% YoY.

**【CFO Financial Commentary】**
- **2024 Financials**: 
  - Full year revenue: $79.9M (22% YoY growth). 
  - Gross margin: 75.4% (Q4) / 75.2% (2023 Q4). 
  - Net loss: $5.3M (Q4) vs. $6.2M prior year. 
  - Cash balance: $52.8M as of Dec 31, 2024.
- **2025 Guidance**: 
  - Revenue: $92-96M (15-20% YoY growth). 
  - Gross margin: 73-75%. 
  - Operating expenses: $92-95M.
- **Capital Raise**: Completed $69.8M public offering, repurchased 5.3M shares from KCK, ending ATM program.

**【Q&A Highlights】**
- **Project CARE Contribution**: Q4 implants/referrals grew sequentially, with >2x 2025 target. CARE 2.0 initiatives to accelerate growth.
- **NAUTILUS Timeline**: Data lock and FDA submission in H2 2025, with high-profile publication planned.
- **Pediatric Strategy**: Leveraging real-world data and NEST collaboration for indication expansion.
- **Gross Margin Drivers**: Volume growth, pricing, and contract discipline. 2025 margin guide reflects DIXI product mix variability.
- **Cash Flow Breakeven**: Long-range plan targets cash flow breakeven, with $68.6M pro forma cash as of Feb 28, 2025.

Actual	-32.73	-0.48	-0.34	-0.44	-0.47	-0.52	-0.48	-0.45	-0.41	-0.36	-0.28	-0.23	-0.32	-0.26	-0.19	-0.18	-0.21	-0.26	-0.11	-0.08
Forecast	-0.2367	-0.3357	-0.304	-0.33	-0.4425	-0.45	-0.5275	-0.5	-0.4575	-0.47	-0.404	-0.315	-0.3213	-0.3	-0.2686	-0.2229	-0.2409	-0.2229	-0.1953	-0.1561
Surprise	-13727.63%	-42.98%	-11.84%	-33.33%	-6.21%	-15.56%	+9.00%	+10.00%	+10.38%	+23.40%	+30.69%	+26.98%	+0.40%	+13.33%	+29.26%	+19.25%	+12.83%	-16.64%	+43.68%	+48.75%

NPCE

NPCE fundamentals

NPCE Q4 2025 Earnings

Earnings Call

You can ask Aime

NPCE

NPCE fundamentals

NPCE Q4 2025 Earnings

Earnings Call

NPCE Earnings Call Summary for Q4/20254:30 PM on Mar 3, 2026

NPCE Earnings Call Summary for Q3/20254:30 PM on Nov 4, 2025

NPCE Earnings Call Summary for Q2/20254:30 PM on Aug 12, 2025

NPCE Earnings Call Summary for Q1/20254:30 PM on May 13, 2025

NPCE Earnings Call Summary for Q4/20244:30 PM on Mar 4, 2025

You can ask Aime